Table 1. CTLA-4 blockade influences T cell diversity.

nd, sample was not evaluated.

Number of pre/post pairs with fold change in
diversity* >2-fold in either direction
Treatment
1
Treatment
2
Treatment
3
OverallTotal
pairs
Prostate131293476
Melanoma12ndnd1221
Combined251294697
Untreated
controls
00009

*Diversity metric is the number of clones represented in the top 25% by ranked molecule count. The metric was determined pre-post for three sequential treatments (1, 2, and 3) separated by 1-month intervals.

Overall anti–CTLA-4–treated versus normal, P = 0.005 (Fisher’s exact test, two-tailed).